R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Amit Sanyal, MD: A Clinician’s Perspective

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

May

Today In Oncology

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Amit Sanyal, MD: A Clinician’s Perspective

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation

CLL Linked to Increased Skin Cancer Risk and Mortality

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Zoldonrasib in Patients With KRAS G12D NSCLC Previously Treated With Chemoimmunotherapy

Early-Onset ICI-Related Myocarditis Linked to Increased Mortality